NEW YORK, May 20, 2015 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of Open, Transparent and Connected financial marketplaces, today announced CohBar, Inc. (TSX-V: COB.U; OTCQX: CWBR), an innovative biotechnology company focused on developing mitochondria-based therapeutics to treat diseases associated with aging, has qualified to trade on the OTCQX® Best Marketplace.
CohBar begins trading today on OTCQX under the symbol "CWBR." U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com.
"We are proud to welcome CohBar to the family of established, investor-focused U.S. and international companies on our OTCQX marketplace," said R. Cromwell Coulson, President and CEO of OTC Markets Group. "Trading on OTCQX will help CohBar increase its profile with U.S. investors through efficient trading and wide distribution of its news and financial disclosure. We look forward to supporting CohBar in its continued growth and evolution as a publicly-traded company."
"We believe that CohBar's pipeline of mitochondria-based therapeutics has the potential to significantly improve the healthy life-span of our aging population while, at the same time, creating significant value for our investors," said Jon Stern, CEO of CohBar. "Our trading on the OTCQX provides U.S. investors with the opportunity to acquire CohBar shares, which until now have been readily available only in the Canadian marketplace. It also expands our market reach and audience to support future capital needs as we continue to advance our exploitation of this new arena of mitochondria-based medicine."
Garvey Schubert Barer serves as CohBar's Designated Advisor for Disclosure ("DAD") on OTCQX, responsible for providing professional guidance on OTCQX requirements and U.S. securities laws.
CohBar is a leader in the research and development of mitochondria-based therapeutics (MBTs), an emerging class of drugs for the treatment of diseases associated with aging. MBTs originate from the discovery by CohBar's founders of a novel group of peptides within the genome of mitochondria, the powerhouses of the cell. MBTs offer the potential to address a broad range of diseases such as type 2 diabetes, cancer, atherosclerosis and neurodegenerative disorders.
CohBar's scientific leadership is centered around the expertise of its founders, Dr. Pinchas Cohen, Dean of the Davis School of Gerontology at the University of Southern California, and Dr. Nir Barzilai, Professor of Genetics and Director of the Institute for Aging Research at the Albert Einstein College of Medicine, and is supported by its co-founders, Dr. David Sinclair, Professor of Genetics at Harvard Medical School, and Dr. John Amatruda, former Senior Vice President and Franchise Head for Diabetes and Obesity at Merck Research Laboratories. CohBar's Chief Scientific Officer is Dr. Kenneth Cundy, former Chief Scientific Officer at Xenoport, Inc. and Senior Director of Biopharmaceutics at Gilead Sciences, Inc.
About OTC Markets Group Inc.
OTC Markets Group Inc. (OTCQX: OTCM) operates Open, Transparent and Connected financial marketplaces for 10,000 U.S. and global securities. Through our OTC Link® ATS, we directly link a diverse network of broker-dealers that provide liquidity and execution services for a wide spectrum of securities. We organize these securities into marketplaces to inform investors of opportunities and risks: the OTCQX® Best Marketplace; the OTCQB® Venture Marketplace; and the OTC Pink® Open Marketplace. Our data-driven platform enables investors to easily trade through the broker of their choice at the best possible price and empowers a broad range of companies to improve the quality and availability of information for their investors. To learn more about how we create better informed and more efficient financial marketplaces, visit www.otcmarkets.com.
OTC Link ATS is operated by OTC Link LLC, member FINRA/SIPC and SEC regulated ATS.
Saskia Sidenfaden, OTC Markets Group Inc., +1 (212) 896-4428, firstname.lastname@example.org
SOURCE OTC Markets Group Inc.